When endocrine therapy + CDK4/6 inhibitor fails, what next?
Education Alert
Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer
0.25 CPD
What's really the difference between HER2-negative and HER2-low disease? See how this distinction impacts real treatment decisions.
 

Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC

FDA Accepts NDA for Bezuclastinib Combo in Gastrointestinal Stromal Tumors

New Career Center Video:  
Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.

Videos Trending    

Learn strategies and diagnostic options with patient cases
Education Alert
The Clock Is Ticking: Diagnostic Strategies for Timely Sepsis Intervention
0.50 CME / CE / ABIM MOC
How can you overcome diagnostic uncertainty with rapid tests and evidence-based strategies for timely sepsis care?
 

Education Alert
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
0.50 CME / CE / ABIM MOC
Did you know that approximately 50% of breast cancer patients who have been exposed to an AI over time in the metastatic setting develop an ESR1 mutation?    

Education Alert
Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy
0.50 CME / ABIM MOC
Are you regularly testing for TRK fusions in cancers with high fusion frequency?


 

Learn how inflammatory mechanisms drive COPD pathophysiology
Education Alert
IL-33 in COPD: The Alarmin Signal Driving Inflammation and Tissue Damage
15 min EBAC
How do different inflammatory pathways contribute to the pathophysiology of COPD, and what is the role of IL???33?
 

Education Alert
Episode 1: The Need for Targeted Biologic Intervention in COPD
15 min EBAC
Get up to date on the complex heterogeneity of chronic obstructive pulmonary disease and the latest therapies available to treat it.

Optimizing First-Line Treatment in EGFR+ mNSCLC: Balancing Efficacy, CNS Control, and Safety
This program provides an in-depth discussion on the evolving treatment strategies for patients with EGFR-mutant metastatic non-small cell lung cancer (mNSCLC), emphasizing the role of combination therapies to improve survival outcomes. Experts review recent clinical trial data, particularly focusing on central nervous system (CNS)-active regimens such as amivantamab plus lazertinib and osimertinib combinations. They highlight patient selection, emphasizing high-risk populations with CNS metastases or high tumor burden, and discuss the clinical rationale for early, aggressive therapy versus de-escalation approaches. Safety, tolerability, and patient-centered care are emphasized, including management of adverse events and considerations for quality of life.

Featured Video
CNS Disease and Intracranial Management in EGFR-Mutant mNSCLC
Experts discuss the efficacy of amivantamab and lazertinib in treating EGFR mutations, highlighting improved outcomes and reduced CNS metastases.